Barton Parish, MD
Adult Medicine · Hot Springs, ARNPI 1013922988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 39.6% of the total.
Across 195 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$347
- Pfizer$223
- Lilly USA, LLC$205
- Amgen$176
- Novo Nordisk$141
- plus $642 from 18 others
What the payments were for
- Food & beverage$2,870100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,136 |
| GSK | 24 | $347 |
| Pfizer | 13 | $223 |
| Lilly USA, LLC | 14 | $205 |
| Amgen(2 entities) | 11 | $176 |
| Novo Nordisk | 9 | $141 |
| AstraZeneca | 6 | $103 |
| Abbott | 4 | $63 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Exact Sciences | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Shield Therapeutics Inc | 3 | $45 |
| Astellas Pharma US Inc | 2 | $40 |
| Edwards Lifesciences | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
Too few adult medicine providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $58,257 |
| EliquisApixaban | 50 | $55,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $44,919 |
| FarxigaDapagliflozin Propanediol | 45 | $36,876 |
| VraylarCariprazine Hcl | 17 | $34,077 |
| JardianceEmpagliflozin | 24 | $23,961 |
| JanuviaSitagliptin Phosphate | 11 | $19,450 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,054 |
| TrulicityDulaglutide | 11 | $10,654 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $9,623 |
| Repatha SureclickEvolocumab | 12 | $9,189 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $6,109 |
| Pregabalin | 61 | $4,602 |
| Gabapentin | 144 | $3,241 |
| Epinephrine | 19 | $2,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $141 | $58,25755 claims |
| PfizerEliquis | $223 | $55,84350 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $103 | $48,93064 claims |
| GSKTrelegy Ellipta | $347 | $44,91943 claims |
| AbbVieVraylar | $1,136 | $34,07717 claims |
| MerckJanuvia | $18 | $19,45011 claims |
| Lilly USA, LLCTrulicity | $205 | $10,65411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other adult medicine in Hot Springs
- Jheanelle DawkinsSherwood$4K
- Jessica SearsFayetteville$2K
- Gil JohnsonConway$984
- Charles CarttarLittle Rock$749
- Diata HartLittle Rock$528
- Donna BeallisSpringdale$219
- Muhammad Omar KhanFort Smith$125
- Johnny PaineSearcy$118
- Valerie ShelbyFort Smith$98
- Archie HearneLittle Rock$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.